{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CD137",
    "query": {
      "intervention": "CD137"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CD137&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T06:47:53.267Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00803374",
      "title": "Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "AntiCD137",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-11",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2011-11-21",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00803374"
    },
    {
      "nct_id": "NCT01114256",
      "title": "FNA Tumor Sampling for CD137 Modulation: A Pilot Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Breast Cancer",
        "Head and Neck Cancers",
        "Non-Hodgkin Lymphoma",
        "Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "FNA Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2010-03",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2017-08-03",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01114256"
    },
    {
      "nct_id": "NCT03330561",
      "title": "PRS-343 in HER2-Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER2-positive Bladder Cancer",
        "HER2-positive Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PRS-343",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pieris Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2017-09-13",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03330561"
    },
    {
      "nct_id": "NCT00351325",
      "title": "A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Malignancies"
      ],
      "interventions": [
        {
          "name": "BMS-663513",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2007-09",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2009-09-04",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 4,
      "location_summary": "Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Charlottesville, Virginia + 1 more",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00351325"
    },
    {
      "nct_id": "NCT02451982",
      "title": "Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "GVAX pancreatic cancer",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Urelumab",
          "type": "DRUG"
        },
        {
          "name": "BMS-986253",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2016-03-28",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451982"
    },
    {
      "nct_id": "NCT05190445",
      "title": "Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cinrebafusp alfa (PRS-343) in combination with tucatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pieris Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2021-11-01",
      "completion_date": "2023-02-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-08",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 4,
      "location_summary": "Santa Barbara, California • Silver Spring, Maryland • New York, New York + 1 more",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05190445"
    },
    {
      "nct_id": "NCT01853631",
      "title": "Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells",
          "type": "GENETIC"
        },
        {
          "name": "Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2014-02",
      "completion_date": "2036-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853631"
    },
    {
      "nct_id": "NCT04903873",
      "title": "A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Renal Cell Cancer Metastatic",
        "Non-Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EU101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eutilex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2021-05-31",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903873"
    },
    {
      "nct_id": "NCT04839991",
      "title": "Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced and/or Metastatic Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CB307",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crescendo Biologics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2021-06-08",
      "completion_date": "2024-09-25",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04839991"
    },
    {
      "nct_id": "NCT03922204",
      "title": "A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Solid Tumor, Adult",
        "B-cell Lymphoma, Adult"
      ],
      "interventions": [
        {
          "name": "MCLA-145",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (Keytruda)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merus B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2019-05-08",
      "completion_date": "2024-11-07",
      "has_results": false,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-09-08T06:47:53.267Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03922204"
    }
  ]
}